Klineo

What Klineo does

Klineo is a Paris-based digital health startup founded in 2021 that operates an AI-powered platform connecting oncology patients and healthcare providers with relevant clinical trials for cancer treatment. The platform addresses a stated paradox in oncology: patients struggling to find appropriate trials and physicians lacking efficient tools to match patients to suitable studies. The company's core technology is a recommendation engine that uses AI-based matching to connect patients and doctors with cancer clinical trials; this is the single named proprietary capability and the foundation of the product. Distribution is direct-to-user via a self-serve web application (app.klineo.com), with both patients and oncologists able to access the platform independently. No pricing model, revenue mechanism, or monetization approach is disclosed in available sources, and the company does not list named customers, enterprise contracts, or certifications such as HIPAA/GDPR compliance attestations. The founding team comprises co-founder and CEO Thomas Peyresblanques, co-founder and CTO Nicolas Drizard, CMO Arnaud Bayle, and associate/founder Soha Tohidi.

In April 2024, Klineo closed a €2 million seed round led by BPI France with participation from business angels. Proceeds are allocated to four explicit priorities: (i) expand AI platform coverage to all cancer types in France by end of 2024, (ii) extend into additional European countries and the United States, (iii) broaden beyond oncology into other disease areas, and (iv) expand the team. As of the latest data, Klineo operates with 1-10 employees, making it an early-stage company in build mode. Geographic presence is currently France, with stated expansion targets across Europe and North America. The company has not disclosed revenue, ARR, pricing, or customer logos, and there is no evidence of regulatory milestones (CE marking, FDA submissions) or institutional healthcare partnerships beyond the financial backing of BPI France.

Name

Klineo

Legal name

Klineo

Website

https://klineo.fr

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Klineo is a Paris-based digital health startup operating an AI-powered platform that connects cancer patients and oncologists with relevant clinical trials. Founded in 2021, it is expanding coverage across all cancer types in France and into European and US markets.

Ownership category

akta.pro rank

Product category

Clinical Trial Matching Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industry

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

Keywords

• Clinical trial matching
• Oncology platform
• Digital health
• Patient recruitment
• AI clinical trials

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Core offering

Klineo operates an AI-based digital health platform that connects cancer patients and their physicians with relevant oncology clinical trials. The platform uses an AI-powered recommendation engine to match patient and clinician queries against available cancer trials, aiming to cover all cancer types in France and expand internationally. It serves both individual cancer patients seeking treatment access and oncologists looking to identify appropriate trials for their patients.

Product overview

Klineo offers a single unified AI-powered platform that connects patients and doctors with clinical trials for cancer. The platform uses AI-based matching to help patients find relevant clinical trials and enables doctors to identify appropriate trials for their patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Klineo Platform AI-based digital health platform that connects cancer patients and doctors with relevant clinical trials for cancer treatment. Accessible via a self-serve web application (app.klineo.com).

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Mendel: Mendel offers an AI platform that structures clinical and biomedical data to match patients with eligible trials. It is comparable to Klineo as an AI-first trial matching platform targeting providers and pharma sponsors.
• Massive Bio: Massive Bio is an AI-driven oncology clinical trial enrollment platform operating globally. It is a direct competitor to Klineo in matching cancer patients to trials and engaging sponsors for recruitment services.
• Deep 6 AI: Deep 6 AI uses AI and NLP to match patients to clinical trials by mining structured and unstructured EHR data. It is a direct competitor to Klineo in AI-powered oncology and multi-therapeutic trial matching for providers and sponsors.
• Antidote (by Inspire): Antidote is a long-standing clinical trial search and matching platform connecting patients with trials across multiple therapeutic areas, including oncology. It is the closest direct competitor to Klineo in patient-facing trial matching and sponsor recruitment services.

Broad incumbents

• ClinicalTrials.gov: ClinicalTrials.gov is the US-government-run registry of clinical trials worldwide and a default free resource for trial search. It is a broad incumbent and indirect competitor that constrains monetization of any commercial trial-matching platform.
• TriNetX: TriNetX operates a global health research network used by pharma and providers for protocol design, feasibility, and patient recruitment. It overlaps with Klineo on the provider/sponsor side of oncology trial matching.
• IQVIA: IQVIA is a global CRO and clinical technology provider offering trial recruitment, real-world data, and patient matching services at scale. It is a broad incumbent that competes for pharma sponsor recruitment budgets alongside Klineo's future monetization path.
• EU Clinical Trials Information System (CTIS): CTIS is the EMA-operated portal for EU clinical trial information under the Clinical Trials Regulation. As a regulator-mandated public registry, it represents a free baseline competitor to Klineo in European oncology trial discovery.

Emerging players

• Trial Library: Trial Library focuses on community oncology trial matching, helping community oncologists identify and enroll patients into oncology trials. It overlaps with Klineo's provider-side use case, particularly in oncology.
• Power (subjectwell): Power connects cancer patients to clinical trials via a navigator-led service supported by technology. It is comparable to Klineo as an oncology-focused patient trial navigator with a consumer entry point.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/klineo_fr
• Facebookfacebook.com/KLINEOofficial
• LinkedInlinkedin.com/company/klineosa

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Klineo